EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LakeShore Biopharma Co's enterprise value is $59.59 Mil.
LakeShore Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.66 Mil. Therefore, LakeShore Biopharma Co's EV-to-EBITDA for today is -5.11.
The historical rank and industry rank for LakeShore Biopharma Co's EV-to-EBITDA or its related term are showing as below:
LSBCF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 12.965 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
LakeShore Biopharma Co (OTCPK:LSBCF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LakeShore Biopharma Co's PE Ratio (TTM) for today is calculated as:
LakeShore Biopharma Co's share price for today is $0.067.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.717.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSBCF vs ACUT, PPCB, ENSC: EV-to-EBITDA Comparison
For the Biotechnology subindustry, LakeShore Biopharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LakeShore Biopharma Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LakeShore Biopharma Co's EV-to-EBITDA falls into.
LakeShore Biopharma Co's current Enterprise Value is $59.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LakeShore Biopharma Co (LSBCF) has a EV-to-EBITDA of -5.11 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LakeShore Biopharma Co.
Is LakeShore Biopharma Co's EV-to-EBITDA too high?
LakeShore Biopharma Co's current EV-to-EBITDA is -5.11.
How does LakeShore Biopharma Co's EV-to-EBITDA compare to ACUT and PPCB?
LakeShore Biopharma Co's EV-to-EBITDA of -5.11 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 12.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.97, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LakeShore Biopharma Co. For the Biotechnology industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current EV-to-EBITDA is -5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current EV-to-EBITDA of -5.11. The current EV-to-EBITDA is -5.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current EV-to-EBITDA is -5.11 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSBCF has been successfully added to your 